Event Date/Time: Jan 15, 2012
End Date/Time: Jan 20, 2012
Jan 15, 2012
Early Registration Date:
Nov 15, 2011
Hundreds of millions of people world-wide are infected each year with protozoan parasites. The mortality and morbidity associated with these diseases are expected to increase due to the development of drug resistant parasites, the absence of adequate vaccines and a shortage of anti-protozoan agents in the drug development pipelines. Understanding the pathogenesis, mechanisms of growth and differentiation, and metabolic processes of the parasites has provided new insights and challenges in the identification of novel drug targets for malaria, leishmaniasis and trypanosomiasis. Integrated strategies combining target identification and validation with advances in structural biology, genetic manipulations and high-throughput high-content screening platforms are likely to accelerate the development of anti-protozoan drugs. This meeting is the only international meeting that addresses the development of drugs to treat and prevent parasite infections. Parasitologists, chemists, pharmacologists and clinicians from academia, government and industry will come together at this meeting to discuss opportunities for the advancement of novel anti-protozoan chemotypes and progression of lead compounds into clinical development. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Fungal Pathogens: From Basic Biology to Drug Discovery, which will share a keynote address and two plenary sessions with this meeting.
This meeting is held jointly with the Keystone Symposia meeting "Fungal Pathogens: From Basic Biology to Drug Discovery."
Registering for one meeting in a set of joint meetings enables participateion in sessions of the otehr, pending space availability.
Global Health Travel Award deadline - August 16, 2011
Abstract & scholarship - September 19, 2011
Late-breaking abstract - October 19, 2011